青少年和年轻成人癌症患者接种非mRNA疫苗后对SARS-CoV-2的体液和细胞免疫:一项前瞻性队列研究
该前瞻性研究招募了118例12-30岁正在接受癌症治疗或已结束治疗的青少年和年轻成人患者,评估接种非mRNA疫苗后的体液和细胞免疫应答。结果显示,全队列抗RBD抗体滴度从基线到第二剂后6周升高(p=0.001),但第一剂到第二剂后无显著变化(p=0.842);BECOV-2疫苗与较BBV152更高的抗体滴度独立相关。作者认为,单剂非mRNA疫苗可提供稳健的混合体液免疫,第二剂获益有限。
要点
- 全队列抗RBD抗体对数滴度从基线到第二剂后6周升高(p=0.001),第一剂到第二剂后无显著变化(p=0.842)。
- BECOV-2疫苗与较BBV152更高的抗RBD对数滴度独立相关(回归系数0.41;95%CI 0.10-0.73;p=0.011)。
- 细胞免疫应答在正在治疗组和已结束治疗组的三个时间点相似。
核心结论
- 在青少年和年轻成人癌症患者中,单剂非mRNA疫苗可提供稳健的混合体液免疫,第二剂获益有限。
研究设计与样本
- 前瞻性研究,2022年4月至12月招募118例12-30岁正在接受癌症治疗(正在治疗组)和已结束治疗(已结束治疗组)的患者,中位年龄15.4岁。
- 其中77例(65.2%)在正在治疗组,77例(65.2%)接种了BBV152疫苗。
- 在基线、第一剂后4周(T1)和第二剂后6周(T2)测量抗受体结合域(RBD)蛋白IgG水平;在部分患者中采用激活诱导标志物和细胞内细胞因子染色评估细胞免疫。
主要发现
- 基线时108例(91.5%)患者抗RBD抗体血清阳性。
- 全队列抗RBD对数滴度从基线到T2升高(p=0.001);从基线到T1升高显著(p<0.001),但从T1到T2无显著变化(p=0.842)。
- 正在治疗组呈现相似模式。
- BECOV-2疫苗与较BBV152更高的抗RBD对数滴度独立相关(回归系数0.41;95%CI 0.10-0.73;p=0.011)。
- 细胞免疫应答在正在治疗组和已结束治疗组的三个时间点相似。
临床怎么用
- 作者认为,在青少年和年轻成人癌症患者中,单剂非mRNA疫苗可提供稳健的混合体液免疫,第二剂获益有限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on SARS-CoV-2 vaccine responsiveness in adolescent/young adult (AYA) cancer patients are sparse. The present study assessed humoral and cellular immune responses post-vaccination in this population. METHODS: In this prospective study, patients aged 12-30 years undergoing cancer therapy ("on therapy") and survivors ("off therapy") were recruited. Anti-receptor binding domain (RBD) protein IgG levels were measured at baseline, four weeks post-first vaccine dose (T1), and six weeks post-second dose (T2). Cellular immunity was assessed using activation-induced markers and intracellular cytokine staining in a patient subset. The primary outcome was to quantify humoral responses in both cohorts at T2 compared to baseline. Clinical predictors of log antibody titres at T2 were identified. RESULTS: Between April-December 2022, 118 patients were recruited of median age 15.4 years. Among them, 77 (65.2 %) were in the "on therapy" group, and 77 (65.2 %) had received the BBV152 vaccine. At baseline, 108 (91.5 %) patients were seropositive for anti-RBD antibody. The log anti-RBD titre rose from baseline to T2 (p-value = 0.001) in the whole cohort; this rise was significant from baseline-T1 (p-value < 0.001), but not from T1 to T2 (p-value = 0.842). A similar pattern was seen in the "on therapy" cohort. BECOV-2 vaccine was independently associated with higher log anti-RBD titres than BBV152 (regression coefficient: 0.41; 95 % CI: 0.10-0.73; p = 0.011). Cellular immune responses were similar in the "on-" and "off therapy" groups at the three time points. CONCLUSION: Among AYA cancer patients, a single non-mRNA vaccine dose confers robust hybrid humoral immunity with limited benefit from a second dose.
引用
- Sasi A, Dandotiya J, Kaushal J, et al. Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study. Vaccine. 2024. PMID: 38514355. doi:10.1016/j.vaccine.2024.03.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。